Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

Published:2010-01-18 Issue:3 Volume:51 Page:475-480
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kantarjian Hagop M.,Thomas Deborah,Ravandi Farhad,Faderl Stefan,Garcia-Manero Guillermo,Shan Jianquin,Pierce Sherry,Cortes Jorge,O'Brien Susan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428190903503412

Reference19 articles.

1. Acute Lymphoblastic Leukemia

2. Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy

3. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

4. RECENT CLINICAL TRIALS IN ACUTE LYMPHOCYTIC LEUKEMIA BY THE CANCER AND LEUKEMIA GROUP B

5. THE MEDICAL RESEARCH COUNCIL TRIALS IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol;eJHaem;2024-08-08

2. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction;Journal of Oncology Pharmacy Practice;2019-02-13

3. Poor Penetration of Existing Effective Chemoimmunotherapy for the Treatment of Older Patients With Newly Diagnosed Acute Lymphocytic Leukemia (ALL) or Refractory/Relapsed ALL;Journal of Oncology Practice;2019-02

4. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation;Anti-Cancer Drugs;2017-11

5. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia;Drugs of Today;2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3